Journal of Clinical Oncology November 13, 2026

Dasatinib Dose Optimization With Weekend Drug Holiday for Improved Tolerability in Chronic Myeloid Leukemia (DasaHIT): A German Chronic Myeloid Leukemia Alliance Randomized Trial

Paul La Rosée et al.

Bottom Line

In patients with first-line chronic phase CML, an intermittent dasatinib dosing schedule with weekend holidays was noninferior to continuous daily dosing for achieving major molecular remission at 24 months, with fewer pleural and pericardial effusions.

Key Findings

1. In the overall evaluable first-line population, major molecular remission (MMR) at 24 months was achieved by 81% (105 of 130) in the standard continuous arm [95% CI, 74% to 88%] compared to 78% (101 of 130) in the experimental weekend holiday arm [95% CI, 71% to 85%], demonstrating noninferiority within the prespecified 15% margin (P = .009).
2. In patients treated in the second- or later-line setting, the intermittent dosing schedule failed to demonstrate noninferiority, as MMR at 24 months was 24% lower than in the continuous dosing group.
3. A post hoc analysis revealed that toxicities of special interest (pleural or pericardial effusion) were significantly reduced in the intermittent dosing arm (8%, 10 of 125 patients) compared to the standard continuous dosing arm (16%, 21 of 130 patients) (P = .0464).
4. Health-related quality of life showed improvement primarily in first-line patients, favoring the experimental intermittent dosing schedule.
5. There was no significant difference between the two treatment arms regarding overall grade 2-4 toxicities.

Study Design

Design
RCT
Open-Label
Sample
289
Patients
Duration
24 mo
Median
Setting
Multicenter, Germany
Population Patients with chronic phase chronic myeloid leukemia (CP-CML), predominantly receiving first-line treatment (80%)
Intervention Intermittent dasatinib schedule (100 mg daily for 5 days on, followed by 2 days [weekend] off)
Comparator Standard-of-care continuous dasatinib 100 mg once daily
Outcome Coprimary endpoints of achievement of major molecular remission (MMR) at 24 months and a newly developed cumulative toxicity score

Study Limitations

• The intermittent dosing strategy failed noninferiority in the second- or later-line setting, restricting its applicability strictly to first-line therapy.
• The statistically significant reduction in pleural and pericardial effusions was identified through a post hoc analysis rather than a prespecified primary or secondary safety endpoint, warranting cautious interpretation.
• The open-label nature of the trial could introduce bias into subjective coprimary endpoints such as health-related quality of life and cumulative toxicity scoring.

Clinical Significance

This trial validates a pragmatic dose de-escalation strategy for patients receiving dasatinib as first-line therapy for CP-CML. Implementing a two-day "weekend holiday" maintains molecular efficacy while significantly cutting the incidence of debilitating class-specific toxicities like pleural effusions, ultimately enhancing quality of life. However, clinicians must avoid this intermittent schedule in patients receiving dasatinib in second-line or later settings, where continuous dosing remains essential for disease control.

Historical Context

Tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia, transforming it from a fatal disease into a manageable chronic condition with near-normal life expectancy. However, continuous, indefinite TKI therapy is often accompanied by chronic, low-grade cumulative toxicities and significant financial burden. Dasatinib, a second-generation TKI, is particularly associated with dose- and schedule-dependent pleural effusions that often lead to drug discontinuation. In recent years, treatment paradigms have shifted toward dose optimization, striving to find the minimum effective dose required to maintain major molecular remissions while minimizing chronic adverse effects.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

What is the mechanism of action of dasatinib in chronic myeloid leukemia, and how does its target profile explain both its efficacy and its characteristic side effect of pleural effusions?

Key Response

Dasatinib is a second-generation dual BCR-ABL and Src family tyrosine kinase inhibitor. Its potent inhibition of the BCR-ABL fusion protein drives the major molecular remissions in CML. However, its off-target inhibition of Src family kinases (like LCK) and PDGFR in the pulmonary and pleural vasculature alters vascular permeability and immune regulation, leading to the classic side effect of pleural effusions, which the DasaHIT trial sought to mitigate.

Resident
Resident

A patient with newly diagnosed chronic phase CML is started on dasatinib. Based on the DasaHIT trial results, if the patient begins to develop recurrent mild pleural effusions on continuous dosing, what evidence-based dosing strategy could be employed before abandoning the drug entirely?

Key Response

The DasaHIT trial demonstrated that implementing a weekend drug holiday (e.g., 5 days on, 2 days off) is non-inferior to continuous dosing for achieving Major Molecular Remission at 24 months, while significantly reducing the incidence of pleural and pericardial effusions. Thus, a resident should consider an intermittent dosing schedule to manage or prevent recurrent effusions rather than immediately switching to a different TKI.

Fellow
Fellow

Given that dasatinib has a relatively short plasma half-life of 3 to 5 hours, how does the pharmacological and molecular rationale justify maintaining major molecular remission despite a 48-hour weekend drug holiday in the DasaHIT trial?

Key Response

Although dasatinib has a short plasma half-life, it exhibits profound, rapid, and irreversible-like inhibition of BCR-ABL kinase activity. Transient profound kinase inhibition is sufficient to trigger apoptosis in CML progenitors. The weekend holiday exploits this 'hit-and-run' kinetic by allowing brief periods for off-target tissue recovery to reduce pleural effusions, without allowing sufficient time for the leukemic clone to recover or develop resistance, thereby maintaining non-inferior MMR rates.

Attending
Attending

How might the formalized weekend drug holiday from the DasaHIT trial paradoxically improve long-term real-world efficacy compared to continuous dosing, and how should we counsel patients regarding strict adherence to the 5-days-on schedule?

Key Response

While continuous dosing is the traditional standard, TKI fatigue and chronic adverse events often lead to unmonitored non-adherence or complete drug discontinuation, which drives resistance. A prescribed weekend holiday can improve overall quality of life and adherence to the regimen. However, attendings must explicitly counsel patients that 'intermittent' does not mean 'as needed'; strict adherence to the 5-day on schedule is mandatory to maintain the therapeutic pressure necessary for deep molecular responses.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

In designing a non-inferiority trial for an intermittent TKI dosing strategy like DasaHIT, how does the selection of the non-inferiority margin for Major Molecular Remission at 24 months impact statistical power, and what competing risks must be modeled when evaluating the secondary time-to-effusion endpoints?

Key Response

The non-inferiority margin must be clinically acceptable so that any potential loss of efficacy is offset by the safety gain. If the margin is too wide, an unacceptably inferior regimen might be adopted; if too narrow, the trial requires an unfeasibly large sample size. Furthermore, competing risks analysis (e.g., Fine-Gray modeling) is essential for the safety endpoint, as patients discontinuing the drug for reasons other than effusions (such as disease progression or other toxicities) compete with the time-to-effusion event and can bias Kaplan-Meier estimates.

Journal Editor
Journal Editor

What are the primary threats to validity in the DasaHIT trial regarding an open-label design, and how might investigator bias influence the reporting and grading of subjective components of adverse events like mild pleural effusions?

Key Response

In an open-label trial testing a dosing reduction strategy specifically designed to reduce effusions, both patients and investigators are unblinded to the treatment arms. This can lead to ascertainment bias or a differential threshold for investigating and grading mild pleural effusions (e.g., ordering fewer chest X-rays in the holiday arm). A rigorous reviewer would demand to see objective, standardized imaging screening protocols across both arms to ensure the primary safety endpoint was not skewed by this bias.

Guideline Committee
Guideline Committee

Considering current ELN and NCCN guidelines recommend continuous daily TKI dosing for first-line chronic phase CML, does the DasaHIT trial provide sufficient Level 1 evidence to formally recommend weekend drug holidays as a universal standard first-line option, or should it be reserved strictly as a toxicity management strategy?

Key Response

Current ELN and NCCN guidelines emphasize continuous daily dosing to achieve early and deep molecular responses, which correlate with long-term survival. While DasaHIT shows non-inferiority at 24 months with reduced toxicity, guideline committees must weigh whether this justifies a universal shift in upfront recommendations or if it should be incorporated as a Grade 2A recommendation specifically for toxicity mitigation in patients at high risk for effusions. Committees would likely require longer follow-up (e.g., 5-year data on progression-free survival and resistance mutations) before universally endorsing intermittent dosing for all newly diagnosed patients.

Clinical Landscape

Noteworthy Related Trials

2008

CA180-034 Trial

n = 670 · JCO

Tested

Dasatinib 100 mg once daily

Population

CML patients resistant or intolerant to imatinib

Comparator

Dasatinib 50 mg twice daily, 140 mg once daily, or 70 mg twice daily

Endpoint

Major cytogenetic response at 6 months

Key result: Dasatinib 100 mg once daily showed similar efficacy but significantly reduced pleural effusion and other adverse events compared to twice-daily or higher dose regimens.
2010

DASISION Trial

n = 519 · NEJM

Tested

Dasatinib 100 mg once daily

Population

Newly diagnosed chronic-phase CML patients

Comparator

Imatinib 400 mg once daily

Endpoint

Confirmed complete cytogenetic response by 12 months

Key result: Dasatinib induced higher and faster rates of complete cytogenetic and major molecular responses compared to imatinib.
2017

DESTINY Trial

n = 174 · Lancet Haematol

Tested

De-escalation of TKI therapy to half standard dose for 12 months

Population

Chronic-phase CML patients with stable major molecular response

Comparator

Baseline full-dose TKI (single-arm de-escalation study)

Endpoint

Proportion of patients maintaining major molecular response at 12 months

Key result: Reducing the TKI dose by half was safe and maintained response in the vast majority of patients while significantly improving side-effect profiles.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis
↑